Uses
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin[1][2].
References
[1] Dhimolea E. Canakinumab. MAbs. Epub 2010 Jan 15. DOI:
10.4161/mabs.2.1.10328[2] Rondeau JM, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015;7(6):1151-60. DOI:
10.1080/19420862.2015.1081323
